Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Regression of Fibrosis After Direct-acting Antivirals Treatment of Patients with Hepatitis C Virus Cirrhosis: Transposability to Nondecompensated Patients.

Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F.

J Clin Exp Hepatol. 2019 Jul-Aug;9(4):546. doi: 10.1016/j.jceh.2018.10.007. Epub 2018 Nov 8. No abstract available.

PMID:
31516272
2.

Updates in the field of non-esophageal gastroesophageal reflux disorder.

Ghisa M, Della Coletta M, Barbuscio I, Marabotto E, Barberio B, Frazzoni M, De Bortoli N, Zentilin P, Tolone S, Ottonello A, Lorenzon G, Savarino V, Savarino E.

Expert Rev Gastroenterol Hepatol. 2019 Sep;13(9):827-838. doi: 10.1080/17474124.2019.1645593. Epub 2019 Jul 22.

PMID:
31322443
3.

The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication.

Savarino V, Marabotto E, Zentilin P, Savarino E.

Expert Rev Clin Pharmacol. 2019 Nov;12(11):1011-1012. doi: 10.1080/17512433.2019.1643199. Epub 2019 Jul 17. No abstract available.

PMID:
31305167
4.

Advancements in the use of manometry and impedance testing for esophageal functional disorders.

Savarino E, Marabotto E, Bodini G, Furnari M, Della Coletta M, Ghisa M, Barberio B, Frazzoni M, De Bortoli N, Zentilin P, Pellegatta G, Tolone S, Ottonello A, Savarino V.

Expert Rev Gastroenterol Hepatol. 2019 May;13(5):425-435. doi: 10.1080/17474124.2019.1595587. Epub 2019 Mar 21.

PMID:
30896306
5.

Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.

Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, Facchin S, Lorenzon G, Marchi S, Marabotto E, De Bortoli N, Savarino V, Costa F, Blandizzi C.

Expert Opin Biol Ther. 2019 Feb;19(2):79-88. doi: 10.1080/14712598.2019.1561852. Epub 2019 Jan 2. Review.

PMID:
30574820
6.

Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals.

Giannini EG, Crespi M, Demarzo M, Bodini G, Furnari M, Marabotto E, Torre F, Zentilin P, Savarino V.

Eur J Clin Invest. 2019 Mar;49(3):e13056. doi: 10.1111/eci.13056. Epub 2018 Dec 19.

PMID:
30474209
7.

Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations.

Crespi M, Ghidotti I, Bodini G, Furnari M, Marabotto E, Giannini EG.

Dig Liver Dis. 2019 Jan;51(1):173-174. doi: 10.1016/j.dld.2018.09.025. Epub 2018 Oct 1. No abstract available.

PMID:
30366811
8.

Proton pump inhibitors: use and misuse in the clinical setting.

Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E.

Expert Rev Clin Pharmacol. 2018 Nov;11(11):1123-1134. doi: 10.1080/17512433.2018.1531703. Epub 2018 Oct 10. Review.

PMID:
30295105
9.

NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis.

Giannini EG, Bodini G, Furnari M, Marabotto E.

J Hepatol. 2018 Oct;69(4):972-973. doi: 10.1016/j.jhep.2018.05.016. Epub 2018 Jul 4. No abstract available.

PMID:
30227919
10.

Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: The perfect storm.

Giannini EG, Bodini G, Furnari M, Marabotto E.

Liver Int. 2018 Nov;38(11):2101. doi: 10.1111/liv.13962. Epub 2018 Oct 8. No abstract available.

PMID:
30223302
11.

A safety review of proton pump inhibitors to treat acid-related digestive diseases.

Savarino E, Marabotto E, Zentilin P, Furnari M, Bodini G, Pellegatta G, Lorenzon G, Della Coletta M, Ghisa M, Coppo C, Marinelli C, Savarino V.

Expert Opin Drug Saf. 2018 Aug;17(8):785-794. doi: 10.1080/14740338.2018.1497155. Epub 2018 Jul 23. Review.

PMID:
30035645
12.

A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients.

Giannini EG, Bodini G, Furnari M, Marabotto E.

Am J Gastroenterol. 2019 Feb;114(2):364-365. doi: 10.1038/s41395-018-0128-2. No abstract available.

PMID:
29910461
13.

Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn.

Marabotto E, Furnari M, Giannini EG, Savarino V, Savarino E.

Aliment Pharmacol Ther. 2018 Jul;48(1):107-108. doi: 10.1111/apt.14800. No abstract available.

PMID:
29882977
14.

The appropriate use of proton-pump inhibitors.

Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, Pellegatta G, Coppo C, Savarino E.

Minerva Med. 2018 Oct;109(5):386-399. doi: 10.23736/S0026-4806.18.05705-1. Epub 2018 May 31. Review.

PMID:
29856192
15.

Effects of bariatric surgery on the esophagus.

Savarino E, Marabotto E, Savarino V.

Curr Opin Gastroenterol. 2018 Jul;34(4):243-248. doi: 10.1097/MOG.0000000000000439. Review.

PMID:
29846257
16.

Drugs for improving esophageal mucosa defense: where are we now and where are we going?

Savarino E, Zentilin P, Marabotto E, Pellegatta G, Coppo C, Brunacci M, Dulbecco P, Savarino V.

Ann Gastroenterol. 2017;30(6):585-591. doi: 10.20524/aog.2017.0187. Epub 2017 Aug 17. Review.

17.

Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis.

Zentilin P, Savarino V, Marabotto E, Murdaca G, Sulli A, Pizzorni C, Puppo F, Savarino E.

Semin Arthritis Rheum. 2018 Feb;47(4):569-574. doi: 10.1016/j.semarthrit.2017.08.004. Epub 2017 Aug 9.

PMID:
28870413
18.

A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).

Savarino E, Zentilin P, Marabotto E, Bodini G, Della Coletta M, Frazzoni M, de Bortoli N, Martinucci I, Tolone S, Pellegatta G, Savarino V.

Expert Opin Pharmacother. 2017 Sep;18(13):1333-1343. doi: 10.1080/14656566.2017.1361407. Epub 2017 Aug 7. Review.

PMID:
28754071
19.

Vonoprazan fumarate for the management of acid-related diseases.

Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E.

Expert Opin Pharmacother. 2017 Aug;18(11):1145-1152. doi: 10.1080/14656566.2017.1346087. Epub 2017 Jul 6. Review.

PMID:
28657473
20.

Complexity and diversity of gastroesophageal reflux disease phenotypes.

Zentilin P, Marabotto E, Pellegatta G, Coppo C, Furnari M, Savarino E, Savarino V.

Minerva Gastroenterol Dietol. 2017 Sep;63(3):198-204. doi: 10.23736/S1121-421X.17.02399-6. Epub 2017 Mar 7. Review.

PMID:
28272380
21.

Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease.

Savarino E, Zentilin P, Marabotto E, Savarino V.

J Neurogastroenterol Motil. 2017 Apr 30;23(2):318-319. doi: 10.5056/jnm17027. No abstract available.

22.

Epidemiology and natural history of gastroesophageal reflux disease.

Savarino E, Marabotto E, Bodini G, Pellegatta G, Coppo C, Giambruno E, Brunacci M, Zentilin P, Savarino V.

Minerva Gastroenterol Dietol. 2017 Sep;63(3):175-183. doi: 10.23736/S1121-421X.17.02383-2. Epub 2017 Feb 17. Review.

PMID:
28215067
23.

Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index.

Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, Marabotto E, Savarino V, Savarino E.

Dig Liver Dis. 2017 Feb;49(2):175-180. doi: 10.1016/j.dld.2016.10.014. Epub 2016 Nov 2.

PMID:
27864028
24.

The natural history of gastro-esophageal reflux disease: a comprehensive review.

Savarino E, de Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, Ottonello A, Marabotto E, Bodini G, Savarino V.

Dis Esophagus. 2017 Feb 1;30(2):1-9. doi: 10.1111/dote.12511. Review.

PMID:
27862680
25.

Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD.

de Bortoli N, Frazzoni L, Savarino EV, Frazzoni M, Martinucci I, Jania A, Tolone S, Scagliarini M, Bellini M, Marabotto E, Furnari M, Bodini G, Russo S, Bertani L, Natali V, Fuccio L, Savarino V, Blandizzi C, Marchi S.

Am J Gastroenterol. 2016 Dec;111(12):1711-1717. doi: 10.1038/ajg.2016.432. Epub 2016 Sep 20.

PMID:
27644732
26.

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis.

Savarino E, Zentilin P, Marabotto E, Savarino V.

J Neurogastroenterol Motil. 2016 Oct 30;22(4):710-711. doi: 10.5056/jnm16120. No abstract available.

27.

Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.

Savarino E, Martinucci I, Furnari M, Romana C, Pellegatta G, Moscatelli A, Bodini G, Marabotto E, Savarino V, de Bortoli N, Blandizzi C.

Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1333-1341. doi: 10.1080/17425255.2016.1214714. Epub 2016 Aug 8.

PMID:
27428571
28.

Reduction of hexavalent chromium by fasted and fed human gastric fluid. I. Chemical reduction and mitigation of mutagenicity.

De Flora S, Camoirano A, Micale RT, La Maestra S, Savarino V, Zentilin P, Marabotto E, Suh M, Proctor DM.

Toxicol Appl Pharmacol. 2016 Sep 1;306:113-9. doi: 10.1016/j.taap.2016.07.004. Epub 2016 Jul 9.

29.

Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.

Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E.

J Gastrointestin Liver Dis. 2015 Dec;24(4):451-6. doi: 10.15403/jgld.2014.1121.244.adb.

30.

Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?

Tolone S, De Bortoli N, Marabotto E, de Cassan C, Bodini G, Roman S, Furnari M, Savarino V, Docimo L, Savarino E.

Neurogastroenterol Motil. 2015 Oct;27(10):1423-31. doi: 10.1111/nmo.12638. Epub 2015 Jul 30.

PMID:
26227513
31.

Optimal management of constipation associated with irritable bowel syndrome.

Furnari M, de Bortoli N, Martinucci I, Bodini G, Revelli M, Marabotto E, Moscatelli A, Del Nero L, Savarino E, Giannini EG, Savarino V.

Ther Clin Risk Manag. 2015 May 30;11:691-703. doi: 10.2147/TCRM.S54298. eCollection 2015. Review.

32.

Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD.

Tolone S, de Cassan C, de Bortoli N, Roman S, Galeazzi F, Salvador R, Marabotto E, Furnari M, Zentilin P, Marchi S, Bardini R, Sturniolo GC, Savarino V, Savarino E.

Neurogastroenterol Motil. 2015 Aug;27(8):1175-82. doi: 10.1111/nmo.12606. Epub 2015 May 25.

PMID:
26010058
33.

Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients.

Savarino E, Bodini G, Marabotto E, Savarino V.

J Neurogastroenterol Motil. 2015 Mar 30;21(2):292-3. doi: 10.5056/jnm14156. No abstract available.

34.

Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope.

Bodini G, Savarino V, Marabotto E, Savarino E.

Clin Gastroenterol Hepatol. 2015 Oct;13(10):1856. doi: 10.1016/j.cgh.2015.01.018. Epub 2015 Jan 28. No abstract available.

PMID:
25638583
35.

Measurement of oro-caecal transit time by magnetic resonance imaging.

Savarino E, Savarino V, Fox M, Di Leo G, Furnari M, Marabotto E, Gemignani L, Bruzzone L, Moscatelli A, De Cassan C, Sardanelli F, Sconfienza LM.

Eur Radiol. 2015 Jun;25(6):1579-87. doi: 10.1007/s00330-014-3575-1. Epub 2015 Jan 11.

36.

Comment on "impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis" by Marzio Frazzoni et al. [Digestive and Liver Disease 2014;46:596-602].

Savarino E, Marabotto E, Bartolo O, de Cassan C.

Dig Liver Dis. 2014 Nov;46(11):1052. doi: 10.1016/j.dld.2014.06.012. Epub 2014 Jul 28. No abstract available.

PMID:
25081845
37.

Esophageal motility abnormalities in gastroesophageal reflux disease.

Martinucci I, de Bortoli N, Giacchino M, Bodini G, Marabotto E, Marchi S, Savarino V, Savarino E.

World J Gastrointest Pharmacol Ther. 2014 May 6;5(2):86-96. doi: 10.4292/wjgpt.v5.i2.86. Review.

38.

Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease.

Savarino E, Zentilin P, Furnari M, Bodini G, Marabotto E, Savarino V.

J Neurogastroenterol Motil. 2014 Jan;20(1):129-30. doi: 10.5056/jnm.2014.20.1.129. No abstract available.

39.

Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.

Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, Frigo AC, Fazio V, Marabotto E, Savarino V.

Am J Gastroenterol. 2013 Nov;108(11):1731-42. doi: 10.1038/ajg.2013.287. Epub 2013 Sep 10.

PMID:
24019080
40.

Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients.

Savarino E, Carbone R, Marabotto E, Furnari M, Sconfienza L, Ghio M, Zentilin P, Savarino V.

Eur Respir J. 2013 Nov;42(5):1322-31. doi: 10.1183/09031936.00101212. Epub 2013 Mar 7.

41.

Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn.

Savarino E, Zentilin P, Mastracci L, Dulbecco P, Marabotto E, Gemignani L, Bruzzone L, de Bortoli N, Frigo AC, Fiocca R, Savarino V.

J Gastroenterol. 2013 Apr;48(4):473-82. doi: 10.1007/s00535-012-0672-2. Epub 2012 Sep 25.

PMID:
23001252
42.

Overweight is a risk factor for both erosive and non-erosive reflux disease.

Savarino E, Zentilin P, Marabotto E, Bonfanti D, Inferrera S, Assandri L, Sammito G, Gemignani L, Furnari M, Dulbecco P, Savarino V.

Dig Liver Dis. 2011 Dec;43(12):940-5. doi: 10.1016/j.dld.2011.07.014. Epub 2011 Sep 22.

PMID:
21944835
43.

Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease.

Savarino E, Gemignani L, Pohl D, Zentilin P, Dulbecco P, Assandri L, Marabotto E, Bonfanti D, Inferrera S, Fazio V, Malesci A, Tutuian R, Savarino V.

Aliment Pharmacol Ther. 2011 Aug;34(4):476-86. doi: 10.1111/j.1365-2036.2011.04742.x. Epub 2011 Jun 14.

44.

The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease.

Savarino E, Marabotto E, Zentilin P, Frazzoni M, Sammito G, Bonfanti D, Sconfienza L, Assandri L, Gemignani L, Malesci A, Savarino V.

Dig Liver Dis. 2011 Jul;43(7):542-7. doi: 10.1016/j.dld.2011.01.016. Epub 2011 Mar 3.

PMID:
21376679
45.

Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers.

Savarino E, Zentilin P, Frazzoni M, Cuoco DL, Pohl D, Dulbecco P, Marabotto E, Sammito G, Gemignani L, Tutuian R, Savarino V.

Neurogastroenterol Motil. 2010 Oct;22(10):1061-e280. doi: 10.1111/j.1365-2982.2010.01536.x. Epub 2010 Jun 17.

PMID:
20557468
46.

[Possible connection between gastroesophageal reflux and interstitial pulmonary fibrosis in patients with systemic sclerosis].

Savarino E, Ghio M, Marabotto E, Zentilin P, Sammito G, Cittadini G, Sconfienza L, Murolo C, Gemignani L, Indiveri F, Savarino V.

Recenti Prog Med. 2009 Nov;100(11):512-6. Review. Italian.

PMID:
20066883
47.

Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy.

Savarino E, Tutuian R, Zentilin P, Dulbecco P, Pohl D, Marabotto E, Parodi A, Sammito G, Gemignani L, Bodini G, Savarino V.

Am J Gastroenterol. 2010 May;105(5):1053-61. doi: 10.1038/ajg.2009.670. Epub 2009 Dec 8.

PMID:
19997095
48.

Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.

Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, Isola L, De Conca S, Marabotto E, Savarino V.

J Clin Gastroenterol. 2009 Nov-Dec;43(10):962-6. doi: 10.1097/MCG.0b013e3181a099a5.

PMID:
19525858
49.

Hepatocellular carcinoma in patients with cryptogenic cirrhosis.

Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M; Italian Liver Cancer (ITALICA) Group.

Clin Gastroenterol Hepatol. 2009 May;7(5):580-5. doi: 10.1016/j.cgh.2009.01.001.

PMID:
19418607
50.

Hyaluronic acid and aspartate aminotransferase levels normalized by liver function can reflect sinusoidal impairment in chronic liver disease.

Testa E, Malfatti F, Milazzo S, Cordiviola C, Cotellessa T, Marabotto E, Giannini E, Ceppa P, Mamone M, Risso D, Testa R.

Liver Int. 2006 May;26(4):439-44.

PMID:
16629647

Supplemental Content

Loading ...
Support Center